Description: Rare diseases are an important public-health issue and a challenge for the medical community. Most rare diseases are genetic disorders, which are often severely disabling, substantially affect life expectancy, and impair physical and mental abilities.Currently, there are about 7,000 identified rare diseases, together affecting 10% of the population. However, fewer than 6% of all rare diseases have an approved treatment option, highlighting their tremendous unmet needs in drug development. The process of repurposing drugs for new indications, compared with the development of novel orphan drugs, is a time-saving and cost-efficient method resulting in higher success rates, which can therefore drastically reduce the risk of drug development for rare diseases.
Rare diseases are an important public-health issue and a challenge for the medical community. Most rare diseases are genetic disorders, which are often severely disabling, substantially affect life expectancy, and impair physical and mental abilities.Currently, there are about 7,000 identified rare diseases, together affecting 10% of the population. However, fewer than 6% of all rare diseases have an approved treatment option, highlighting their tremendous unmet needs in drug development. The process of repurposing drugs for new indications, compared with the development of novel orphan drugs, is a time-saving and cost-efficient method resulting in higher success rates, which can therefore drastically reduce the risk of drug development for rare diseases.
MCE carefully collects a unique of 1742 compounds studied in preclinical, clinical trials or approved used in rare diseases treatment. MCE rare diseases drug library is a useful tool for the research of rare diseases. All compounds can provide corresponding indications for rare diseases.
MCE Rare Diseases Drug Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 1697 compounds supplied in 10 mM solution, 39 compounds supplied in 2 mM solution and 6 compounds supplied in 3 mg/mL solution.
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.
Advantages:
- A unique collection of 1742 compounds with rare diseases drug for high throughput screening (HTS) and high content screening (HCS).
- A useful tool for the research of rare diseases.
- Target diverse, medicinally active and cell permeable.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.
- More detailed compound information with structure, IC50, and other chemical & biological data.
- High purity and quality validated by NMR and LC/MS.
Formulation: A collection of 1742 rare diseases-related compounds supplied as pre-dissolved Solutions or SolidSolution:1697 compounds supplied in 10 mM solution,39 compounds supplied in 2 mM solution,6 compounds supplied in 3 mg/mL solution.
Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty.384-well plate: the first two columns and the last two columns are left empty.Compounds with different concentrations or dissolved in different solvents will be put on separate plates.This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know.
Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode
English
Deutsch
